Table 2.

Summary of therapeutic targets for siRNA-based treatment of several ocular diseases tested in vivo

Ocular diseases	Target	References
Glaucoma	RhoA	Liu et al., 2012
	Cochlin	Goel et al., 2012
	β2-Adrenoceptor	Mediero et al., 2009; Pintor, 2011
	Na-K-ATPase	Mediero et al., 2009
	Purine receptor P2Y2	Martin-Gil et al., 2012
	c-Jun	Lingor et al., 2005
	Apoptosis regulator Bax	Lingor et al., 2005
	Apaf-1	Lingor et al., 2005
	Caspase-2	Ahmed et al., 2011
Fibrotic eye by glaucoma filtration surgery	TGF-β2	Nakamura et al., 2004
	IκB kinase β	Ye et al., 2010
RP	Rhodopsin	Tessitore et al., 2006; O'Reilly et al., 2007; Mao et al., 2012
	Retinal degeneration slow-peripherin	Petrs-Silva et al., 2012
	Guanylate cyclase 2	Tosi et al., 2011
	Cyclic nucleotide-gated ion channels	Tosi et al., 2011
AMD	VEGF	Reich et al., 2003
	VEGFR1	Shen et al., 2006
	RTP801	Nozaki et al., 2006
DR	VEGF	Reich et al., 2003
	VEGFR1	Shen et al., 2006
	RTP801	Brafman et al., 2004
	HIF-1α	Jiang et al., 2009
	Fibronectin	Roy et al., 2003
	Connective tissue growth factor	Yang et al., 2010a; 2010b; Winkler et al., 2012
	TXNIP	Perrone et al., 2010; Sbai et al., 2010; Devi et al., 2012
Corneal neovascularization	VEGF	Kim et al., 2004; Singh et al., 2007; Zuo et al., 2010; Qazi et al., 2012
	VEGFR1	Kim et al., 2004
	HIF-1α	Chen et al., 2012
	Cytochome P450 enzyme CYP4B1	Seta et al., 2007
	Cannabinoid CB1 receptor	Pisanti et al., 2011